ADYX - Adynxx, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.3500
0.0000 (0.00%)
At close: 10:20AM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.3500
Open0.3500
Bid0.0000 x 800
Ask0.0000 x 1300
Day's Range0.3500 - 0.3500
52 Week Range0.3100 - 18.4800
Volume182
Avg. Volume1,668
Market Cap2.033M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.8190
Earnings DateNov 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMay 05, 2019
1y Target Est2.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Adynxx Reports Third Quarter 2019 Financial Results

      SAN FRANCISCO, Nov. 14, 2019 -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and.

    • GlobeNewswire

      Adynxx Receives NIH HEAL Initiative Funding Award for Development of Second Non-Opioid Pain Therapeutic

      Adynxx, Inc. (ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced the receipt of a Notice of Award for $602,516 from the National Institute on Neurological Disease and Stroke (NINDS), part of the National Institutes of Health (NIH), to support development of AYX2, the company’s product candidate intended to treat chronic pain. As previously announced, in December 2018 Adynxx received an award from the National Institute on Drug Abuse (NIDA), part of the NIH, for up to $15 million to support clinical development of its lead program, brivoligide, which is being studied in Phase 2 clinical trials for postoperative pain.

    • GlobeNewswire

      Adynxx Reports Second Quarter 2019 Financial Results

      SAN FRANCISCO, Aug. 14, 2019 -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and.

    • GlobeNewswire

      Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market

      Adynxx, Inc. (ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced that Gregory J. Flesher, Chief Executive Officer at Novus Therapeutics Inc. (NVUS), has been appointed to the Adynxx Board of Directors. In addition, Adynxx also announced today that it satisfied the requirements for listing of the Company’s shares on the OTCQB Market (OTCQB) and will begin trading on the OTCQB today.

    • GlobeNewswire

      Adynxx Stock to Move to OTC Market Following Receipt of Nasdaq Delisting Notice

      Adynxx, Inc. (ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced that it has received written notification from The Nasdaq Stock Market affirming the delisting of the company's shares from The Nasdaq Capital Market due to noncompliance with the minimum round lot stockholders and the minimum stockholders’ equity requirement for an initial listing. The notification indicates that Nasdaq will complete the delisting process by filing a Form 25 “Notification of Delisting” with the SEC after all applicable Nasdaq review and appeal periods have lapsed. In accordance with Nasdaq’s Listing Rules, Adynxx has 15 days to decide whether to appeal the delisting determination, and the company is considering an appeal of the determination. Any such appeal would not stay the suspension of trading in the company’s common stock on Nasdaq.

    • GlobeNewswire

      Adynxx, Inc. Receives Nasdaq Notice of Delisting or Failure to Satisfy an Initial Listing Rule or Standard

      Adynxx, Inc. (Nasdaq:ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced that it received a Staff Delisting Determination Letter from The Nasdaq Stock Market, LLC on May 6, 2019 setting forth a determination to delist Adynxx’s common stock from The Nasdaq Capital Market as a result of Adynxx’s failure to satisfy Nasdaq Listing Rule 5505(a)(3), which requires a minimum of 300 round lot holders, and Nasdaq Listing Rule 5505(b)(1)(A), which requires a minimum of $5 million in stockholders’ equity. In connection with the consummation of the merger of Adynxx with Alliqua BioMedical, Inc. and the commencement of trading of the combined organization’s common stock on The Nasdaq Capital Market, Adynxx previously announced that it expected to receive a delisting determination notifying Adynxx that Nasdaq has determined, among other things, that the combined organization does not satisfy the minimum stockholders’ equity requirement for initial listing on The Nasdaq Capital Market.